EC Clinical and Medical Case Reports

Review Article Volume 6 Issue 7 - 2023

New Therapeutic Options for Chronic Renal Failure: Improvement of Cellular Functions and Internal Dialysis Hypothesis

Ahed J Alkhatib1,2,3*

1Department of Legal Medicine, Toxicology and Forensic Medicine, Jordan University of Science and Technology, Jordan

2International Mariinskaya Academy, Department of Medicine and Critical Care, Department of Philosophy, Academician Secretary of Department of Sociology, Jordan

3Cypress International Institute University, Texas, USA

*Corresponding Author: Ahed J Alkhatib, Department of Legal Medicine, Toxicology and Forensic Medicine, Jordan University of Science and Technology, Jordan.
Received: May 25, 2023; Published: June 29, 2023



Chronic renal failure (CRF) is a condition that refers to the gradual impairment of kidney function that occurs over the course of time. In advanced situations, the treatment modality that is utilized most frequently is renal dialysis. The primary purpose of this investigation was to suggest a novel therapeutic method for CRF and to conduct a literature assessment on the most recent developments in this area. We proposed a new therapeutic method based on the expansion of the notion of internal dialysis to be mediated by activated charcoal and to improve the function of renal cells through the supplementation with natural antioxidants such as Ammi visnaga and Urtica pilulifera. This new approach would be mediated by activated charcoal. In conclusion, the findings demonstrated that patients who were willing to try out this therapy method had been successful in improving their CRF levels on kidney function tests including creatinine, urea, and potassium. These patients had had positive outcomes as a result of these improvements.

Keywords: Renal Failure; CRF; Creatinine; Urea; Activated Charcoal; Dialysis

  1. Li J., et al. “Exosomes derived from mesenchymal stem cells attenuate the progression of a rat model of chronic kidney disease via internalization and regulation of mRNAs”. Stem Cell Research and Therapy1 (2020): 228.
  2. Zhang Y., et al. “Mesenchymal stem cell-derived extracellular vesicles improve renal microvasculature in a rat model of chronic kidney disease”. Stem Cell Research and Therapy 1 (2021): 267.
  3. Perico N., et al. “Autologous mesenchymal stromal cells and kidney transplantation: A pilot study of safety and clinical feasibility”. Clinical Journal of the American Society of Nephrology 5 (2018): 673-682.
  4. Reinders ME., et al. “Safety and feasibility of intravenous allogeneic umbilical cord-derived mesenchymal stem cell therapy in patients with kidney transplant rejection: a pilot study”. Stem Cell Research and Therapy 1 (2021): 9.
  5. Rossert J. “Erythropoietin in chronic kidney disease”. Current Opinion in Nephrology and Hypertension 4 (2018): 251-256.
  6. Mohan S., et al. “A novel mechanism of erythropoietin-induced cardioprotection: evidence that erythropoietin promotes autophagy via activation of JAK2-STAT3 signaling pathway”. Journal of Pharmacology and Experimental Therapeutics 3 (2020): 524-535.
  7. Bagshaw SM., et al. “Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes”. Clinical Journal of the American Society of Nephrology 3 (2007): 431-439.
  8. Rosenberger C., et al. “Adaptation to hypoxia in the diabetic rat kidney”. Kidney International 1 (2008): 34-42.
  9. Chapman CL., et al. “Kidney physiology and pathophysiology during heat stress and the modification by exercise, dehydration, heat acclimation and aging”. Temperature 2 (2020): 108-159.
  10. Peng Y., et al. “A randomized, controlled trial of adipose-derived mesenchymal stem cells for the treatment of patients with chronic renal failure”. Stem Cells Translational Medicine 6 (2016): 801-808.
  11. Palmer SC., et al. “Meta-analysis: Erythropoiesis-stimulating agents in patients with chronic kidney disease”. Annals of Internal Medicine 9 (2009): 624-635.
  12. Krendel DA and Neilson EG. “Use of activated charcoal in chronic renal failure”. Journal of the American Society of Nephrology 2 (1992): 204-210.
  13. Ghane Shahrbaf F and Assadi F. “Effect of activated charcoal on reducing urea and creatinine serum levels in chronic kidney disease”. Journal of Renal Injury Prevention 1 (2016): 44-47.
  14. Elsherbiny NM., et al. “Combination of Low-Protein Diet and Activated Charcoal Ameliorates Oxidative Stress Markers in Chronic Kidney Disease Patients”. International Journal of Nephrology and Renovascular Disease 14 (2021): 197-206.
  15. DeSchryver-Kecskemeti K and Cluxton RJ Jr. “Activated charcoal: a review of the literature”. Journal of the American Pharmacists Association 1 (1993): 41-48.
  16. Ghane Shahrbaf F and Assadi F. “Effect of activated charcoal on reducing urea and creatinine serum levels in chronic kidney disease”. Journal of Renal Injury Prevention 1 (2017): 44-47.
  17. Tang Y., et al. “Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with chronic kidney disease: a randomized controlled trial”. BMC Nephrology 1 (2020): 264.
  18. Elsherbiny NM., et al. “Combination of Low-Protein Diet and Activated Charcoal Ameliorates Oxidative Stress Markers in Chronic Kidney Disease Patients”. International Journal of Nephrology and Renovascular Disease 14 (2021): 197-206.
  19. Agarwal S., et al. “Lycopene-rich extract from red guava (Psidium guajava Linn.) alleviates the symptoms of renal dysfunction in experimental chronic kidney disease”. Food and Function 10 (2018): 5317-5329.
  20. Eirin A and Lerman LO. “The Emerging Role of Mitochondrial Targeted Peptides in the Treatment of Chronic Kidney Disease”. Antioxidants 2 (2021): 278.
  21. Park S., et al. “Effects of vitamin C supplementation on oxidative stress and inflammation in hemodialysis patients: a randomized controlled trial”. Journal of Renal Nutrition 6 (2016): 401-407.
  22. Krajcovicova-Kudlackova M., et al. “Health benefits and risks of plant proteins”. Bratislavske Lekarske Listy 6-7 (2005): 231-234.
  23. Eguchi K., et al. “Beneficial effects of quercetin on renal function in a rat model of ischemia/reperfusion injury”. Journal of Renal Nutrition 6 (2011): 480-483.
  24. Bhagavathula AS., et al. “Ammi Visnaga in treatment of urolithiasis and hypertriglyceridemia”. Pharmacognosy Research 4 (2014): 397-400.
  25. Abdel-Daim MM., et al. “Protective effects of Ammi visnaga aqueous extract and its active component khellin against adenine-induced chronic kidney disease in rats”. Journal of Medicinal Food 6 (2018): 578-587.
  26. Ahed J Alkhatib. “Two Years follow up of a Patient with Renal Fibrosis: from Renal Transplantation to Normal Functional Restoration Following the Use of Ammi visnaga and Urtica pillulefera”. Archives of Medical Case Reports and Case Study 1 (2020): 3.
  27. Rostami Z., et al. “Khellin improves gentamicin-induced renal dysfunction in rats: The role of oxidative stress, inflammation, apoptosis, and fibrosis”. Journal of Renal Injury Prevention 3 (2016): 126-133.
  28. Alkuraishy HM., et al. “Ammi visnaga supplementation improves lipid profile and ameliorates lipid peroxidation and inflammation in patients with metabolic syndrome”. Journal of Translational Medicine 1 (2015): 358.
  29. Fouque D., et al. “A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease”. Kidney International 4 (2008): 391-398.
  30. Tavafi M., et al. “Urtica dioica extract attenuates nephrotoxicity induced by reno-protective dose of cyclosporine A in rats”. Journal of Nephrology, Dialysis and Transplantation 11 (2012): 4110-4117.
  31. Razavi BM., et al. “Review on the ethnobotany, phytochemistry, and pharmacology of the genus Urtica”. Journal of Acupuncture and Meridian Studies 5 (2017): 323-332.
  32. Ibrahim MA., et al. “Urtica pillulifera: A review on its traditional uses, phytochemistry and pharmacological properties”. Journal of Ethnopharmacology 268 (2021): 113599.
  33. Hafizur RM., et al. “Urtica dioica L.: An alternative therapy for the management of chronic renal failure”. Saudi Journal of Kidney Diseases and Transplantation 1 (2012): 9-14.
  34. Tepe B., et al. “Protective effect of Urtica pilulifera extract against carbon tetrachloride-induced kidney injury in rats”. Journal of Medicinal Food 10 (2013): 904-910.
  35. Bahadoran Z., et al. “Potential efficacy of nettle (Urtica dioica) in management of blood glucose and lipid profile in patients with type 2 diabetes: A randomized double-blind placebo-controlled clinical trial”. Journal of Diabetes and Metabolic Disorders 1 (2019): 139-146.
  36. AlShuwayeb MH and Al-Khatib AJ. “Molecular and chemical therapeutic features of Urtica species”. European Scientific Journal 24 (2013).
  37. AlKhatib AJ., et al. “Leaf Extract of U. Pilulifera Downregulates the Expression of Inos in Kidneys of Diabetic Rats”. European Scientific Journal 21 (2014).
  38. Alkhatib Ahed J., et al. “Urtica Pilulifera Upregulates the Expression of Heat Shock Protein (Hsp70) In Kidneys of Diabetic Rats”. European Scientific Journal 21 (2014).

Ahed J Alkhatib. "New Therapeutic Options for Chronic Renal Failure: Improvement of Cellular Functions and Internal Dialysis Hypothesis." EC Clinical and Medical Case Reports   6.7 (2023): 26-33.